N/A N=74 Antibiotic Efficacy in Pneumonitis Following Paraffin (Kerosene) Ingestion in Children
Kerosene Pneumonitis
Primary: Treatment Failure — 3; 2 participants — p=>0.50
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Woodsmoke Particulate + Prednisone
Airway Inflammation
Primary: Change From Baseline to 4 Hours in Sputum Percent Neutrophils — -2.62; 5.45 percent neutrophils — p=0.24
N/A N=9 Woodsmoke Particulate + Hypertonic Saline
Airway Inflammation
Primary: Change From Baseline to 4 Hours in Sputum Percent Neutrophils — -0.04; -0.5 percent neutrophils — p=> 0.99
Phase 3 N=725 Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
Pneumonia, Bacterial
Primary: Number of Participants Surviving Through LFU Visit — 191; 196; 64; 57 Participants — p=0.4263
N/A N=28 Prophylactic Bronchoscopy After Inhalation Injury in Burn Patients
Inhalation Injury · Pneumonitis · Pneumonia
Primary: All Cause Mortality — 0; 1 participants
N/A N=60 Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street
Asthma
Primary: Spirometry, Percentage Change in FEV1 From Baseline — -1.0; -4.8; -2.2; -7.4 percentage change in FEV1 from baseline — p=<0.05
Early Phase 1 N=22 Quantifying Airway Inflammation With Radiologic Tests
Lung Inflammation
Primary: Change in Ki (Measure of [18F]Fluorodeoxyglucose ([18F]FDG) Uptake Determined by Patlak Graphical Analysis) in the Right Lung 24 Hours After LPS Instillation — 18.8…
N/A N=24 Evaluation of Post-Exposure Sauna Treatment of Firefighters - A Pilot Study
Post-fire Rehabilitation of Firefighters in Sauna
Primary: Urinary Excretion of Hydroxylated PAHs (PAH-OHs) — 10364.2; 40012.1; 6964.1; 22604.3 ng/L — p=0.0000009
N/A N=523 Wood Stove Interventions and Child Respiratory Health
Lower Tract Respiratory Infection
Primary: Number of Participants With at Least One LRTI During Follow-up Period — 16; 20; 17; 138 Participants — p=0.68
Phase 2 N=25 Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
Covid19 · Pneumonia, Viral
Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…
Phase 2 N=158 Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia
Pseudomonas Aeruginosa Pneumonia
Primary: Clinical Cure on Day 21 — 34; 37; 6; 5 Participants — p=0.6154
N/A N=50 Effects of Deployment Exposures on Cardiopulmonary and Autonomic Function
Abnormality, Respiratory System · Autonomic Nervous System
Primary: FEV1 — 0.94; 1.08; 0.95; 1.09 percentage of predicted normal values
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Phase 2 N=66 Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)
Cystic Fibrosis
Primary: Clinically Significant Laboratory Abnormalities. — 1; 0; 8; 7 Participants
Early Phase 1 N=17 Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
N/A N=25 Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer
Breast Carcinoma · Radiation-Induced Dermatitis
Primary: Incidence of Early Adverse Skin Reactions (EASRs) — 13; 10; 4; 6 Participants
Phase 3 N=2,053 Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
Diabetes, Type 1 · Diabetes, Type 2
Primary: Change From Baseline to Month 24 in Forced Expiratory Volume in 1 Second (FEV1) by MMRM for TI vs Usual Care — -0.16; -0.12 liters
Phase 2 N=18 Early Insulin and Development of ARDS
Respiratory Distress Syndrome, Adult · Sepsis · Hyperglycemia
Primary: Plasma Levels of Free Fatty Acids, Tumor Necrosis Factor-α, Interleukin-6, and Von Willebrand Factor Antigen
N/A N=15 Ketone Supplementation in Cystic Fibrosis
Cystic Fibrosis
Primary: Pulmonary Function Testing — 1.9; 2.0 L/sec
N/A N=228 Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filters
Bronchiolitis
Primary: Number of Caregiver-reported Symptom-free Days (SFDs) — 118.01; 112.60 Days — p=0.537